Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet.
Study Goal
The researchers aimed to determine the effects of combining luseogliflozin with a low-carbohydrate diet (LCD) on 24-hour glucose variability in patients with type 2 diabetes.
Results Summary
Luseogliflozin significantly reduced glucose exposure when combined with either a normal-carbohydrate diet (NCD) or LCD, with no observed hypoglycemia. The LCD alone lowered glucose levels compared to NCD, but luseogliflozin with LCD improved glycemic control similarly to luseogliflozin with NCD.
Population
18 Japanese patients with type 2 diabetes.
Effective Dosage
Luseogliflozin 2.5 mg once daily.
Duration
8 days per treatment phase (crossover design).
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
luseogliflozin with a normal-carbohydrate diet | decrease | glucose exposure in terms of the area under the curve over the course of 24 h | Japanese patients with type 2 diabetes | -555.6 mg/dl·h | significantly reduced | #1 |
luseogliflozin with a low-carbohydrate diet | decrease | glucose exposure in terms of the area under the curve over the course of 24 h | Japanese patients with type 2 diabetes | -660.7 mg/dl·h | significantly reduced | #2 |
luseogliflozin with a low-carbohydrate diet | increase | glycaemic control throughout the day | Japanese patients with type 2 diabetes | nearly the same extent as luseogliflozin with the NCD | improved | #3 |
luseogliflozin with a low-carbohydrate diet | no change | hypoglycaemia | Japanese patients with type 2 diabetes | - | without inducing | #4 |
luseogliflozin with a normal-carbohydrate diet | no change | hypoglycaemia | Japanese patients with type 2 diabetes | - | without inducing | #5 |
low-carbohydrate diet | decrease | glucose levels | Japanese patients with type 2 diabetes | - | were lower | #6 |
This randomized, double-blind, placebo-controlled, crossover study was the first to determine the effects of luseogliflozin in combination with a low-carbohydrate diet (LCD) on 24-h glucose variability, assessed by continuous glucose monitoring (CGM). A total of 18 Japanese patients with type 2 diabetes were randomized into two groups, in which patients first received luseogliflozin 2.5 mg once daily then placebo for 8 days each, or vice versa. Patients took luseogliflozin or placebo with a normal-carbohydrate diet (NCD) on day 7 and with the LCD on day 8. CGM was performed on both days. Luseogliflozin significantly reduced glucose exposure in terms of the area under the curve over the course of 24 h when administered with the NCD (difference vs placebo: -555.6 mg/dl·h [1 mg/dl = 0.0556 mmol/l]; p < 0.001) or with the LCD (-660.7 mg/dl·h; p < 0.001). No hypoglycaemia was observed over 24 h with either diet. Although glucose levels were lower with the LCD than with the NCD in the placebo treatment period, luseogliflozin with the LCD improved glycaemic control throughout the day to nearly the same extent as luseogliflozin with the NCD, without inducing hypoglycaemia.